2010년 9월16일 호주 시장보고서: Conquest Mining Limited (ASX:CQT), Shandong Guoda Gold Company Limited와 Mt Carlton 프로젝트(퀸즐랜드 북부 소재) V2 매장지 금, 은, 구리 정광 장기구매계약 체결// Heemskirk Consolidated Limited (ASX:HSK), Pajingo 합작투자사 지분 40%를 Conquest Mining Limited (ASX:CQT)에 매각// Imugene Limited (ASX:IMU), 돼지 생식기 호흡기 증후군(Porcine Reproductive and Respiratory Syndrome, PRRS) 백신 개발 2차시도 성공적으로 완료// Synthesis Energy Systems Inc. (NASDAQ:SYMX)와 Coalworks Limited (ASX:CWK), 2010 Global XTL & IGCC 회의 참석 ‘오클랜드 석탄을 이용한 U-GAS(R)과 MTG 기술을 이용한 액체연료 생산’공동발표
Imugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.